Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading

被引:31
作者
Uzun, O [1 ]
Arikan, S
Kocagöz, S
Sancak, B
Unal, S
机构
[1] Hacettepe Univ, Sch Med, Dept Med, Infect Dis Sect, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Sch Med, Dept Microbiol & Clin Microbiol, TR-06100 Ankara, Turkey
关键词
D O I
10.1016/S0732-8893(00)00177-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Voriconazole is a promising azole effective against a variety of fungi, including yeasts. In this study, we tested in vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against some ATCC and reference strains and 250 clinical yeast isolates. We also evaluated the effect of time of reading on MIC results. Voriconazole was the most active agent against Candida and Trichosporon isolates, including the putatively fluconazole-resistant C. krusei (MIC90 0.25 mu g/ml) and C. glabrata (MIC90 0.5 mu g/ml). Amphotericin B MICs were scattered in a considerably narrow range in both RPMI 1640 and Antibiotic Medium 3. MICs at 24 hours and 48 hours were similar in general for all antifungals tested. The highest percentage of strains that showed 24-hour and 48-hour MICs within +/-1-log(2) dilution was observed for amphotericin B tested in RPMI (99%), and the lowest for amphotericin B tested in Antibiotic Medium 3 (80%). In conclusion, voriconazole is very effective against a wide spectrum of Candida species and 24-hour readings could substitute 48-hour MIC evaluation. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 41 条
[21]   Optimizing voriconazole susceptibility testing of Candida:: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility [J].
Lozano-Chiu, M ;
Arikan, S ;
Paetznick, VL ;
Anaissie, EJ ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) :2755-2759
[22]  
LOZANOCHIU M, 1998, 38 INT C ANT AG CHEM, P456
[23]   In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].
Marco, F ;
Pfaller, MA ;
Messer, S ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163
[24]   In vitro evaluation of voriconazole against some clinically important fungi [J].
McGinnis, MR ;
Pasarell, L ;
Sutton, DA ;
Fothergill, AW ;
Cooper, CR ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1832-1834
[25]   FUNGAL-INFECTIONS IN CANCER-PATIENTS [J].
MEUNIER, F .
CANCER INVESTIGATION, 1991, 9 (02) :151-158
[26]  
National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[27]   Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole [J].
Nguyen, MH ;
Yu, CY .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (01) :141-145
[28]   Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole [J].
Nguyen, MH ;
Yu, CY .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :253-256
[29]   Do in vitro susceptibility data predict the microbiologic response to amphotericin B?: Results of a prospective study of patients with Candida fungemia [J].
Nguyen, MH ;
Clancy, CJ ;
Yu, VL ;
Yu, YC ;
Morris, AJ ;
Snydman, DR ;
Sutton, DA ;
Rinaldi, MG .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) :425-430
[30]   International surveillance of blood stream infections due to Candida species in the European SENTRY program:: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents [J].
Pfaller, MA ;
Jones, RN ;
Doern, GV ;
Fluit, AC ;
Verhoef, J ;
Sader, HS ;
Messer, SA ;
Houston, A ;
Coffman, S ;
Hollis, RJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (01) :19-25